Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association.

Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; Writing Committee Members, Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM.

Circulation. 2010 Aug 3;122(5):537-57. doi: 10.1161/CIR.0b013e3181ee08ed. Epub 2010 Jun 28. No abstract available.

3.

Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.

Perry E.

Am J Health Syst Pharm. 2011 Mar 15;68(6):529-32. doi: 10.2146/ajhp100422. No abstract available.

PMID:
21378302
4.

Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.

Roden DM, Shuldiner AR.

Circulation. 2010 Aug 3;122(5):445-8. doi: 10.1161/CIRCULATIONAHA.110.973362. Epub 2010 Jun 28. No abstract available.

5.

ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA.

Circulation. 2010 Dec 14;122(24):2619-33. doi: 10.1161/CIR.0b013e318202f701. Epub 2010 Nov 8. Review. No abstract available.

6.

Pharmacogenetics testing: implications for cardiovascular therapeutics with clopidogrel and warfarin.

George J, Doney A, Palmer CN, Lang CC.

Cardiovasc Ther. 2010 Jun;28(3):135-8. doi: 10.1111/j.1755-5922.2010.00176.x. No abstract available.

PMID:
20557312
7.

Clopidogrel poor metabolizers may need alternative to standard regimen.

Thompson CA.

Am J Health Syst Pharm. 2010 May 15;67(10):779-80. doi: 10.2146/news100036. No abstract available.

PMID:
20479095
8.

Clopidogrel: to test or not to test? That is the question--still.

Cannon CP.

Clin Chem. 2011 May;57(5):659-61. doi: 10.1373/clinchem.2010.158709. Epub 2011 Mar 14. No abstract available.

9.

[A current problem for regulators. Clopidogrel and pharmacokinetics].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2009;38(4):360-7. doi: 10.1002/pauz.200900326. Review. German. No abstract available.

PMID:
19572363
10.

Need for pharmacogenomic information also for generic medications: recommendation of the European Society of Pharmacogenomics and Theranostics (ESPT).

Seist G.

Drug Metabol Drug Interact. 2012;27(2):119. doi: 10.1515/dmdi-2012-0010. No abstract available.

PMID:
22706235
11.

Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.

Sorich MJ, Polasek TM, Wiese MD.

Clin Pharmacol Ther. 2013 Sep;94(3):376-82. doi: 10.1038/clpt.2013.100. Epub 2013 May 13. Review.

PMID:
23670120
12.

ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

Bhatt DL, Scheiman J, Abraham NS, Antman EM, Chan FK, Furberg CD, Johnson DA, Mahaffey KW, Quigley EM, Harrington RA, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Hlatky MA, Kaul S, Lindner JR, Moliterno DJ, Mukherjee D, Schofield RS, Rosenson RS, Stein JH, Weitz HH, Wesley DJ; American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.

J Am Coll Cardiol. 2008 Oct 28;52(18):1502-17. doi: 10.1016/j.jacc.2008.08.002. No abstract available.

13.

Carriage of reduced-function CYP2C19 allele among patients treated with clopidogrel.

Osnabrugge RL, Kappetein AP, Janssens AC.

JAMA. 2011 Feb 2;305(5):467-8; author reply 468. doi: 10.1001/jama.2011.77. No abstract available.

PMID:
21285422
14.

Clopidogrel and the concept of high-risk pharmacokinetics.

Roden DM, Stein CM.

Circulation. 2009 Apr 28;119(16):2127-30. doi: 10.1161/CIRCULATIONAHA.109.865907. No abstract available.

15.

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Scheiman J, Sperling LS, Tomaselli GF; ACCF/ACG/AHA.

Am J Gastroenterol. 2010 Dec;105(12):2533-49. doi: 10.1038/ajg.2010.445. Review. No abstract available.

PMID:
21131924
16.

Proton pump inhibitors and clopidogrel.

Gaglia MA Jr, Waksman R.

Cardiovasc Ther. 2010 Jun;28(3):169-76. doi: 10.1111/j.1755-5922.2010.00143.x. Epub 2010 Mar 25. Review.

PMID:
20345494
17.

[Clinically relevant interaction between clopidogrel and proton pump inhibitors].

Alban S, Dingermann T, Griese N, Kämmerer W, Schubert-Zsilavecz M, Schulz M, Trenk D, Zagermann-Muncke P.

Pharm Unserer Zeit. 2009;38(4):370-1. doi: 10.1002/pauz.200990048. German. No abstract available.

PMID:
19572357
18.

Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.

Fuster V, Sweeny JM.

JAMA. 2010 Oct 27;304(16):1839-40. doi: 10.1001/jama.2010.1566. No abstract available.

PMID:
20978263
19.

Clinical-scientific notes.

Dick RJ, Byron KA, Dear AE.

Intern Med J. 2012 Oct;42 Suppl 5:7-8. doi: 10.1111/j.1445-5994.2012.02896.x. No abstract available.

PMID:
23035675
20.

Cytochrome P-450 polymorphisms and response to clopidogrel.

Miao J, Liu R, Li Z.

N Engl J Med. 2009 May 21;360(21):2250-1. No abstract available.

PMID:
19469033

Supplemental Content

Support Center